- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 453185, 5 pages
Proteins Reprogramming: Present and Future
Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 0086-510630, China
Received 28 September 2012; Accepted 7 November 2012
Academic Editors: L. Berghella, A. Dricu, and D. X. Tan
Copyright © 2012 Yang Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- K. Takahashi and S. Yamanaka, “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
- X. Y. Zhao, W. Li, Z. Lv et al., “IPS cells produce viable mice through tetraploid complementation,” Nature, vol. 461, no. 7260, pp. 86–90, 2009.
- Y. Fujimoto, M. Abematsu, A. Falk, et al., “Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells,” Stem Cells, vol. 30, no. 6, pp. 1163–1173, 2012.
- Y. W. Jung, E. Hysolli, K. Y. Kim, et al., “Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies,” Current Opinion in Neurology, vol. 25, no. 2, pp. 125–130, 2012.
- L. Ooi, K. Sidhu, A. Poljak, et al., “Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease,” Journal of Neural Transmission. In press.
- J. Liao, C. Cui, S. Chen et al., “Generation of induced pluripotent stem cell lines from adult rat cells,” Cell Stem Cell, vol. 4, no. 1, pp. 11–15, 2009.
- T. Ezashi, B. P. V. L. Telugu, A. P. Alexenko, S. Sachdev, S. Sinha, and R. M. Roberts, “Derivation of induced pluripotent stem cells from pig somatic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 27, pp. 10993–10998, 2009.
- K. Okita, T. Ichisaka, and S. Yamanaka, “Generation of germline-competent induced pluripotent stem cells,” Nature, vol. 448, no. 7151, pp. 313–317, 2007.
- M. Stadtfeld, M. Nagaya, J. Utikal, G. Weir, and K. Hochedlinger, “Induced pluripotent stem cells generated without viral integration,” Science, vol. 322, no. 5903, pp. 945–949, 2008.
- N. Fusaki, H. Ban, A. Nishiyama, K. Saeki, and M. Hasegawa, “Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome,” Proceedings of the Japan Academy B, vol. 85, no. 8, pp. 348–362, 2009.
- K. Okita, H. Hong, K. Takahashi, and S. Yamanaka, “Generation of mouse-induced pluripotent stem cells with plasmid vectors,” Nature Protocols, vol. 5, no. 3, pp. 418–428, 2010.
- K. Woltjen, I. P. Michael, P. Mohseni et al., “PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells,” Nature, vol. 458, no. 7239, pp. 766–770, 2009.
- Y. Junying, H. Kejin, S. O. Kim et al., “Human induced pluripotent stem cells free of vector and transgene sequences,” Science, vol. 324, no. 5928, pp. 797–801, 2009.
- F. Jia, K. D. Wilson, N. Sun et al., “A nonviral minicircle vector for deriving human iPS cells,” Nature Methods, vol. 7, no. 3, pp. 197–199, 2010.
- S. R. Schwarze, K. A. Hruska, and S. F. Dowdy, “Protein transduction: unrestricted delivery into all cells?” Trends in Cell Biology, vol. 10, no. 7, pp. 290–295, 2000.
- H. Matsui, K. Tomizawa, Y. F. Lu, and M. Matsushita, “Protein therapy: In vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery,” Current Protein and Peptide Science, vol. 4, no. 2, pp. 151–157, 2003.
- T. Takenobu, K. Tomizawa, M. Matsushita et al., “Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells,” Molecular cancer therapeutics, vol. 1, no. 12, pp. 1043–1049, 2002.
- M. Inoue, K. Tomizawa, M. Matsushita et al., “p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells,” European Urology, vol. 49, no. 1, pp. 161–168, 2006.
- H. Michiue, K. Tomizawa, F. Y. Wei et al., “The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction,” Journal of Biological Chemistry, vol. 280, no. 9, pp. 8285–8289, 2005.
- H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, vol. 4, no. 5, pp. 381–384, 2009.
- D. Kim, C. H. Kim, J. I. Moon et al., “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell, vol. 4, no. 6, pp. 472–476, 2009.
- E. Vivès, P. Brodin, and B. Lebleu, “A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus,” Journal of Biological Chemistry, vol. 272, no. 25, pp. 16010–16017, 1997.
- S. R. Schwarze, A. Ho, A. Vocero-Akbani, and S. F. Dowdy, “In vivo protein transduction: delivery of a biologically active protein into the mouse,” Science, vol. 285, no. 5433, pp. 1569–1572, 1999.
- W. S. Eum, S. H. Jang, D. W. Kim et al., “Enhanced transduction of Cu,Zn-superoxide dismutase with HIV-1 Tat protein transduction domains at both termini,” Molecules and Cells, vol. 19, no. 2, pp. 191–197, 2005.
- M. Becker-Hapak, S. S. McAllister, and S. F. Dowdy, “TAT-mediated protein transduction into mammalian cells,” Methods, vol. 24, no. 3, pp. 247–256, 2001.
- H. Zhang, Y. Ma, J. Gu, et al., “Reprogramming of somatic cells via TAT-mediated protein transduction of recombinant factors,” Biomaterials, vol. 33, no. 20, pp. 5047–5055, 2012.
- J. P. M. Langedijk, T. Olijhoek, D. Schut, R. Autar, and R. H. Meloen, “New transport peptides broaden the horizon of applications for peptidic pharmaceuticals,” Molecular Diversity, vol. 8, no. 2, pp. 101–111, 2004.
- S. R. Schwarze and S. F. Dowdy, “In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA,” Trends in Pharmacological Sciences, vol. 21, no. 2, pp. 45–48, 2000.
- D. Huangfu, R. Maehr, W. Guo et al., “Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds,” Nature Biotechnology, vol. 26, no. 7, pp. 795–797, 2008.
- J. Liao, Z. Wu, Y. Wang et al., “Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors,” Cell Research, vol. 18, no. 5, pp. 600–603, 2008.
- S. I. Oh, C. K. Lee, K. J. Cho, et al., “Technological progress in generation of induced pluripotent stem cells for clinical applications,” Scientific World Journal, vol. 2012, Article ID 417809, 2012.
- H. Hong, K. Takahashi, T. Ichisaka et al., “Suppression of induced pluripotent stem cell generation by the p53-p21 pathway,” Nature, vol. 460, no. 7259, pp. 1132–1135, 2009.
- T. Lin, R. Ambasudhan, X. Yuan et al., “A chemical platform for improved induction of human iPSCs,” Nature Methods, vol. 6, no. 11, pp. 805–808, 2009.
- M. A. Esteban, T. Wang, B. Qin et al., “Vitamin C enhances the generation of mouse and human induced pluripotent stem cells,” Cell Stem Cell, vol. 6, no. 1, pp. 71–79, 2010.
- P. Mali, B. K. Chou, J. Yen et al., “Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes,” Stem Cells, vol. 28, no. 4, pp. 713–720, 2010.
- P. S. Kabouridis, “Biological applications of protein transduction technology,” Trends in Biotechnology, vol. 21, no. 11, pp. 498–503, 2003.
- S. Sandgren, F. Cheng, and M. Belting, “Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide: role for cell-surface proteoglycans,” Journal of Biological Chemistry, vol. 277, no. 41, pp. 38877–38883, 2002.
- G. Liang, J. He, and Y. Zhang, “Kdm2b promotes induced pluripotent stem cell generation by facilitating gene activation early in reprogramming,” Nature Cell Biology, vol. 14, no. 5, pp. 457–466, 2012.
- J. S. Wadia, R. V. Stan, and S. F. Dowdy, “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis,” Nature Medicine, vol. 10, no. 3, pp. 310–315, 2004.
- J. S. Wadia and S. F. Dowdy, “Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer,” Advanced Drug Delivery Reviews, vol. 57, no. 4, pp. 579–596, 2005.
- M. Silhol, M. Tyagi, M. Giacca, B. Lebleu, and E. Vivès, “Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat,” European Journal of Biochemistry, vol. 269, no. 2, pp. 494–501, 2002.
- T. S. Mikkelsen, J. Hanna, X. Zhang et al., “Dissecting direct reprogramming through integrative genomic analysis,” Nature, vol. 454, no. 7200, pp. 49–55, 2008.
- G. H. Li, W. Li, R. J. Mumper, et al., “Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes,” The FASEB Journal, vol. 26, no. 7, pp. 2824–2834, 2012.
- A. Ho, S. R. Schwarze, S. J. Mermelstein, G. Waksman, and S. F. Dowdy, “Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo,” Cancer Research, vol. 61, no. 2, pp. 474–477, 2001.
- T. Hitsuda, H. Michiue, M. Kitamatsu, et al., “A protein transduction method using oligo-arginine (3R) for the delivery of transcription factors into cell nuclei,” Biomaterials, vol. 33, no. 18, pp. 4665–2672, 2012.
- M. Masip, A. Veiga, J. C. I. Belmonte, and C. Simón, “Reprogramming with defined factors: from induced pluripotency to induced transdifferentiation,” Molecular Human Reproduction, vol. 16, no. 11, pp. 856–868, 2010.
- Y. S. Chun, K. Byun, and B. Lee, “Induced pluripotent stem cells and personalized medicine: current progress and future perspectives,” Anatomy & Cell Biology, vol. 44, no. 4, pp. 245–255, 2011.
- T. Vierbuchen, A. Ostermeier, Z. P. Pang, Y. Kokubu, T. C. Südhof, and M. Wernig, “Direct conversion of fibroblasts to functional neurons by defined factors,” Nature, vol. 463, no. 7284, pp. 1035–1041, 2010.
- Z. P. Pang, N. Yang, T. Vierbuchen, et al., “Induction of human neuronal cells by defined transcription factors,” Nature, vol. 476, no. 7359, pp. 220–223, 2011.
- E. Y. Son, J. K. Ichida, B. J. Wainger, et al., “Conversion of mouse and human fibroblasts into functional spinal motor neurons,” Cell Stem Cell, vol. 9, no. 3, pp. 205–218, 2011.